Charles River Laboratories International, Inc. (CRL)

Market Cap	11.70B
Revenue (ttm)	4.13B
Net Income (ttm)	474.62M
Shares Out	51.35M
EPS (ttm)	9.22
PE Ratio	24.71
Forward PE	20.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	762,872
Open	237.31
Previous Close	239.43
Day's Range	225.97 - 237.31
52-Week Range	161.65 - 275.00
Beta	1.41
Analysts	Buy
Price Target	257.45 (+13.01%)
Earnings Date	May 9, 2024

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 21,800
• Stock Exchange: NYSE
• Ticker Symbol: CRL

Financial Performance

In 2023, CRL's revenue was $4.13 billion, an increase of 3.86% compared to the previous year's $3.98 billion. Earnings were $474.62 million, a decrease of -2.39%.

Analyst Forecast

According to 12 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is $257.45, which is an increase of 13.01% from the latest price.

Price Target

$257.45

(13.01% upside)

Analyst Consensus: Buy